In this opening segment, Dr. Arshad Khanani highlights the SOL-1 phase 3 trial evaluating Axpaxli (OTX-TKI) in treatment-naïve neovascular AMD.
SOL-1 phase 3 Readout: Key Efficacy and Safety Outcomes in Neovascular AMD
Dr. Khanani reviews 52-week safety outcomes, noting Axpaxli was generally well tolerated with no cases of endophthalmitis or retinal vasculitis.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
4
The Residency Report: Cardiovascular risk scores as a window into ocular disease
5